Analytical Data
-
Gene name
CLEC4B2
- Application
-
Alternative Names
Antigen presenting cell lectin-like receptor A1; Aplra1; mDCAR1
-
Species
Rat
-
Source
HEK293
-
Tag
N-6*His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q67DU9
-
Expression Region
M44-L208
-
Protein Length
Partial
-
Molecular Weight
26-40 kDa.
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC4B2, also known as dendritic cell-associated C-type lectin 4 (DC-LAMP), is a member of the C-type lectin receptor family and plays a crucial role in the immune response, particularly within dendritic cells and macrophages. It is involved in pathogen recognition and the modulation of immune signaling pathways, thereby influencing both innate and adaptive immunity. Recent studies have highlighted its potential role in various diseases, including infections, autoimmune disorders, and cancer. The interest in recombinant CLEC4B2 proteins has surged due to their promising applications in immunotherapy and vaccine development. By understanding the structure and function of CLEC4B2, researchers aim to explore its ability to enhance antigen presentation and stimulate T-cell responses. Furthermore, generating recombinant CLEC4B2 offers insights into its molecular interactions and facilititates the investigation of therapeutic strategies that harness its immunological properties. Overall, the study of CLEC4B2 recombinant proteins holds significant potential for advancing immunological research and developing novel treatments for infectious and autoimmune diseases.
